HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health (OTC Drugs)

Set Alert for Health (OTC Drugs)

Regulation/Legislation Explore this Topic

Set Alert for Regulation and Legislation {Health}

Latest From Regulation, Legislation & Health

EU Green Claims Directive: Council Wants Lighter Touch, Especially For SMEs

The European Council adopts its negotiating position with regards to the Green Claims Directive, which aims to prevent greenwashing and empower consumers in making informed, environmentally conscious purchasing decisions. While small and medium-sized enterprises stand to specifically benefit from the Council's more flexible approach, companies in general may be allowed to make certain explicit environmental claims without third-party verification.

Europe Health

US FDA May See Second Straight Year of Non-User Fee Funding Cuts From Congress

The House Appropriations Agriculture, Rural Development, and FDA Subcommittee advanced the FDA’s fiscal year 2025 funding bill, beginning a likely long and difficult budget cycle. 

FDA Legislation

Advisory Committee Consumer Reps Often Fail To Represent Consumer Interests, Groups Tell US FDA

Many positions are vacant or filled by individuals with ties to academia, industry or patient groups, representatives from public interest and consumer groups say during an FDA listening session on advisory committee reforms.

Advisory Committees FDA

US Revamped OTC Monograph Program Changes Start With Acetaminophen Skin Reaction Warning

Proposed change is “the first FDA-initiated proposed order that was not statutorily required” by the 2020 legislation authorizing the agency’s overhaul of the program which makes the large majority of nonprescription drugs available in the US.

OTC Drugs Drug Approval Standards

Supreme Court Mifepristone Decision Sets High Bar For FDA Suits, But Risks To Agency Authority Linger

The unanimous decision that the Alliance for Hippocratic Medicine lacks standing to challenge the FDA’s relaxation of the abortion pill REMS leaves unclear whether the court would have deferred to the agency’s expertise on the merits. 

Women's Health Litigation

NDAC Among US FDA Advisory Committees With Slot Open For Voting Consumer Representative

FDA asks for nominations for voting or non-voting consumer members of its advisory committees. Also wants to hear from consumer organizations interested in participating in selecting consumer representatives for its advisory committees or panels.

Advisory Committees Prescription To OTC Switch
See All

Business Explore this Topic

Set Alert for Business {Health}

Latest From Deals & Health

Get To Know: Fast-Growing, Stigma-Busting, ‘Omnichannel Thinking’ Karo Healthcare

Karo Healthcare has big plans for its expanding range of global OTC brands, the firm reveals in this exclusive Q&A. 

International Health

P&G’s Pantene, Gillette, ZZZQuil Among 30+ Brands Headed To 2024 Olympic Games

Procter & Gamble will feature more than 30 of its brands in Paris 2024 Olympic and Paralympic Games-inspired campaigns spotlighting “Everyday Champions” in its portfolio.

Advertising, Marketing & Sales Deals

Haleon ‘Tight Lipped’ On US Eroxon Roll Out, But Analysts Say 2024 Launch Possible

Haleon says it'll take about 10 more months to bring Futura's Eroxon erectile dysfunction gel to the US. Analysts, however, say it may even arrive before the end of the year, with Haleon already investing significantly in its launch strategy. 

United States Health
See All

Latest From Business Strategies & Health

Alliance Pharma Books £46m Impairment Charge Related To US Menopause Supplement

Alliance Pharma has been hit by a non-cash impairment charge of £46.4m related to its Amberen dietary supplement reflecting the brand's struggles in the US e-commerce market.

Sales & Earnings Dietary Supplements

EU Green Claims Directive: Council Wants Lighter Touch, Especially For SMEs

The European Council adopts its negotiating position with regards to the Green Claims Directive, which aims to prevent greenwashing and empower consumers in making informed, environmentally conscious purchasing decisions. While small and medium-sized enterprises stand to specifically benefit from the Council's more flexible approach, companies in general may be allowed to make certain explicit environmental claims without third-party verification.

Europe Health

UK Medical Device Firm Owen Mumford Launches Pelvic Health Consumer Brand

UK medical devices manufacturer Owen Mumford moves into consumer health with umbrella brand Clariti and OTC relaunch of at-home vaginismus and dyspareunia treatment Amielle Comfort.

Europe United Kingdom
See All

Latest From Sales & Earnings & Health

Alliance Pharma Books £46m Impairment Charge Related To US Menopause Supplement

Alliance Pharma has been hit by a non-cash impairment charge of £46.4m related to its Amberen dietary supplement reflecting the brand's struggles in the US e-commerce market.

Sales & Earnings Dietary Supplements

Marketplace Shows Consumers Bouncing Off Gummy Form Vitamins, Church & Dwight Sees

More than a decade after acquiring vitafusion and L’il Critter gummy vitamin brands and touting gummy as a key growth driver in the VMS space, C&D’s seeing different market trends.

Dietary Supplements Retail

Clear Eyes Production Problems Prestige Consumer Didn’t See Coming Leave Supply On Shelves ‘Spotty’

“Clear Eyes is a perfect example where we're dual-sourced and two facilities don't usually go down at the same time. This was just a quite an anomaly,” says CFO Christine Sacco, noting PCH works with more than 100 contract manufacturers.

OTC Drugs Supply Chain
See All

Latest From Legal Issues & Health

Supreme Court Mifepristone Decision Sets High Bar For FDA Suits, But Risks To Agency Authority Linger

The unanimous decision that the Alliance for Hippocratic Medicine lacks standing to challenge the FDA’s relaxation of the abortion pill REMS leaves unclear whether the court would have deferred to the agency’s expertise on the merits. 

Women's Health Litigation

NAD Oddball: Thermometer Case Administratively Closed As Advertiser Takes Matter To Federal Court

Exergen seeks a declaration from Massachusetts federal court that claims challenged by Baxter in the National Advertising Division forum regarding the accuracy of its thermometers do not constitute false or misleading advertising, if they are even advertising at all.

Advertising, Marketing & Sales Legal Issues

L’Oreal Joins J&J And Major Retailers Defending Benzene Class Actions In Federal Courts

Benzoyl peroxide-based acne drug products and their alleged proclivity to become contaminated with carcinogenic benzene are at the center of putative class actions filing against L’Oreal in federal courts around the US.

Legal Issues Ingredients
See All

Marketing Explore this Topic

Set Alert for Marketing {Health}

Latest From Launches & Health

UK Medical Device Firm Owen Mumford Launches Pelvic Health Consumer Brand

UK medical devices manufacturer Owen Mumford moves into consumer health with umbrella brand Clariti and OTC relaunch of at-home vaginismus and dyspareunia treatment Amielle Comfort.

Europe United Kingdom

Stabilizing Formula Business ‘First And Foremost’ For Perrigo To Reach Sustainable Growth

Perrigo’s adjusted operating income from formula business in 2023 was around half the $140m it expects. Level won’t be reached in 2024 but it’s “well on track to recapturing” that amount in 2025 and to “capturing all of that plus in 2026,” says CEO Patrick Lockwood-Taylor.

Business Strategies OTC Drugs

US Consumer Health Sector Seizing Opportunity To Market Products, Services To GLP-1 Patients

Latest moves on selling to consumers using GLP-1 receptor agonist drugs for obesity come from firms as large as global food products manufacturer and marketer Nestle and as small as startup Promino and as ambitious as men’s health product marketer Ro offering an app at no charge to find GLP-1 drugs.

Consumer Launches
See All

Latest From Ad Campaigns & Health

EU Green Claims Directive: Council Wants Lighter Touch, Especially For SMEs

The European Council adopts its negotiating position with regards to the Green Claims Directive, which aims to prevent greenwashing and empower consumers in making informed, environmentally conscious purchasing decisions. While small and medium-sized enterprises stand to specifically benefit from the Council's more flexible approach, companies in general may be allowed to make certain explicit environmental claims without third-party verification.

Europe Health

UK Medical Device Firm Owen Mumford Launches Pelvic Health Consumer Brand

UK medical devices manufacturer Owen Mumford moves into consumer health with umbrella brand Clariti and OTC relaunch of at-home vaginismus and dyspareunia treatment Amielle Comfort.

Europe United Kingdom

US Consumer Health Sector Seizing Opportunity To Market Products, Services To GLP-1 Patients

Latest moves on selling to consumers using GLP-1 receptor agonist drugs for obesity come from firms as large as global food products manufacturer and marketer Nestle and as small as startup Promino and as ambitious as men’s health product marketer Ro offering an app at no charge to find GLP-1 drugs.

Consumer Launches
See All

Latest From Ad Complaints & Health

EU Green Claims Directive: Council Wants Lighter Touch, Especially For SMEs

The European Council adopts its negotiating position with regards to the Green Claims Directive, which aims to prevent greenwashing and empower consumers in making informed, environmentally conscious purchasing decisions. While small and medium-sized enterprises stand to specifically benefit from the Council's more flexible approach, companies in general may be allowed to make certain explicit environmental claims without third-party verification.

Europe Health

ASA Files: Denigrating Competitors ‘Isn’t A Good Look’ For Advertisers

Bayer Consumer Health and its effervescent vitamin brand Berocca were subjects of denigratory remarks by an online competitor in a recent UK advertising complaint ruling. The ASA’s Freddie Alcock talks HBW Insight through the complaint, explaining in this exclusive interview why denigration is never a good look for advertisers.

United Kingdom Health

ASA Files: It’s Not Just What You Say, But How You Say It

Infirst has been admonished by UK ad authority, ASA, for implying in a TV commercial its lipid-based ibuprofen brand Flarin was more, or uniquely, effective for joint pain relief than other forms of ibuprofen.

United Kingdom Health
See All
UsernamePublicRestriction

Register